Cargando…

Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator

BACKGROUND: The efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS) are well known; however, owing to their high costs, determining real-world outcomes is essential to evaluate the cost-effectiveness of different therapeutic strategies. This study aimed to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romero-Pinel, Lucía, Bau, Laura, Matas, Elisabet, León, Isabel, Juvany, Roser, Jódar, Ramon, Martínez-Yélamos, Antonio, Martínez-Yélamos, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053779/ https://www.ncbi.nlm.nih.gov/pubmed/35486620 http://dx.doi.org/10.1371/journal.pone.0267504

Ejemplares similares

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients
por: Matas, Elisabet, et al.
Publicado: (2014)

Kappa free light chains index in multiple sclerosis very long-term prognosis
por: Arroyo-Pereiro, Pablo, et al.
Publicado: (2023)

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
por: Martínez, M Alba Mañé, et al.
Publicado: (2015)

Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability
por: Casado, Virginia, et al.
Publicado: (2006)

Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series
por: Cobo Calvo, Álvaro, et al.
Publicado: (2013)

Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
por: Fernández, O., et al.
Publicado: (2016)

Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report
por: BLANCAS, ISABEL, et al.
Publicado: (2014)

ATM/MAPK7 crosstalk in cancer
por: Yélamos, José
Publicado: (2017)

Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis
por: Maristany Bosch, Marta, et al.
Publicado: (2021)

Impact of cytomegalovirus infection on B cell differentiation and cytokine production in multiple sclerosis
por: Zabalza, Ana, et al.
Publicado: (2020)

Improving patient outcomes in psoriasis: strategies to ensure treatment adherence
por: Yélamos, Oriol, et al.
Publicado: (2015)

Skin cancer special issue in Skin Health and Disease
por: Yélamos, Oriol, et al.
Publicado: (2023)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

Lentigo Maligna: Clinical Presentation and Appropriate Management
por: Iznardo, Helena, et al.
Publicado: (2020)

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis
por: Andrés-Benito, Pol, et al.
Publicado: (2020)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Ammonium concentration in stream sediments resulting from decades of discharge from a wastewater treatment plant
por: Martín, María Tijero, et al.
Publicado: (2023)

Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease
por: Curto‐Barredo, Laia, et al.
Publicado: (2016)

Crystal structure of (1,3-di-tert-butyl-η(5)-cyclopentadienyl)trimethylhafnium(IV)
por: Pérez-Redondo, Adrián, et al.
Publicado: (2015)

Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours
por: Lutfi, Nura, et al.
Publicado: (2021)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
por: Meca-Lallana, José E., et al.
Publicado: (2023)

Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients
por: Pascual-Guardia, Sergi, et al.
Publicado: (2020)

Geología práctica : introducción al reconocimiento de materiales y análisis de mapas /
por: Pozo Rodríguez, Manuel, et al.
Publicado: (2004)

Attenuation of Muscle Damage, Structural Abnormalities, and Physical Activity in Respiratory and Limb Muscles following Treatment with Rucaparib in Lung Cancer Cachexia Mice
por: Pérez-Peiró, Maria, et al.
Publicado: (2022)

Acceso a medicamentos huérfanos para el tratamiento de la atrofia muscular espinal en España
por: García-Parra, Beliu, et al.
Publicado: (2022)

Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis
por: Lleixà, Cinta, et al.
Publicado: (2023)

Production and characterization of monoclonal antibodies for the detection of the hepatitis C core antigen
por: Vidal-Alcántara, Erick Joan, et al.
Publicado: (2023)

Cost of managing an episode of relapse in multiple sclerosis in the United States
por: O'Brien, Judith A, et al.
Publicado: (2003)

CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
por: Comabella, Manuel, et al.
Publicado: (2021)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
por: Martins, Paulo, et al.
Publicado: (2022)

Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage
por: Pérez-Peiró, Maria, et al.
Publicado: (2023)

Dinitrogen Binding at a Trititanium Chloride Complex and Its Conversion to Ammonia under Ambient Conditions
por: del Horno, Estefanía, et al.
Publicado: (2022)

Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain
por: Mañá, Juan, et al.
Publicado: (2017)

Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis
por: Lopez-Soley, Elisabet, et al.
Publicado: (2021)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
por: Ginestal, Ricardo, et al.
Publicado: (2023)

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
por: Mankinen, Petri, et al.
Publicado: (2019)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis
por: Nicholas, Jacqueline, et al.
Publicado: (2020)

Influence of Brewer’s Spent Grain Compounds on Glucose Metabolism Enzymes
por: Becker, Daniela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3g3ak544fo3psldqv4c4gj9g2v